A diagnosis of muscle-invasive bladder cancer (MIBC) — cancer that has grown into the thick muscle wall of the bladder — often brings one immediate question: Does the entire bladder have to come out?

For most people with MIBC, radical cystectomy (surgery to remove the entire bladder) is the primary treatment option. However, some bladder-preserving approaches may be options for carefully selected people. One is trimodality therapy, which combines transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy. Another is partial cystectomy (surgery to remove only part of the bladder).

This article explains how a partial cystectomy compares with other approaches, who may qualify, and how the long-term benefits balance against the risks.

How Does Partial Cystectomy Differ From Other MIBC Treatments?

A partial cystectomy removes only the part of the bladder that contains cancer, along with a rim of nearby healthy tissue. The rest of the bladder stays in place. Only about 5 percent to 10 percent of people diagnosed with MIBC are candidates for this surgery because the tumor usually needs to be:

• Small
• In one area
• In a location where it can be removed safely

Partial Cystectomy vs. Radical Cystectomy

Radical cystectomy removes the entire bladder and nearby lymph nodes (small, bean-shaped structures that are part of the immune system and can be one of the first places cancer spreads).

For males, radical cystectomy typically includes removing the prostate and seminal vesicles, though prostate-sparing techniques may be considered in some cases.

Partial cystectomy removes only the diseased segment of the bladder.

For females, the exact organs removed can vary based on where the cancer is and how far it has spread. In some cases, surgeons may be able to spare the uterus, ovaries, or both. In other cases, removing nearby reproductive organs may be recommended.

As part of a radical cystectomy, urine is rerouted permanently through a urinary diversion (a new way for urine to leave the body). This may involve:

• An ileal conduit — Sends urine into a small external bag worn under clothing
• A continent internal pouch — Stores urine inside the body until it’s drained with a catheter
• An orthotopic neobladder — Uses part of the intestine to create a new bladder that may allow urination through the urethra

Partial cystectomy removes only the diseased segment of the bladder. When it goes well, a person may still urinate naturally — no bag, no pouch, no diversion. That difference in everyday life is what makes bladder-sparing surgery worth exploring for some people living with MIBC.

Partial Cystectomy vs. Trimodality Therapy

Trimodality therapy is another bladder-sparing approach. It doesn’t remove the bladder and usually doesn’t require major abdominal surgery, meaning there are no large belly incisions.

Trimodality therapy starts with TURBT to remove as much of the tumor as possible through the urethra, followed by chemotherapy and external beam radiation therapy.

The primary drawback of a partial cystectomy is the risk of cancer returning in the remaining part of the bladder.

Partial cystectomy, by contrast, is surgery — done with open, robotic, or laparoscopic techniques — to remove part of the bladder.

Both approaches aim to keep the bladder, but they suit different situations:

• Trimodality therapy is a more common bladder-sparing alternative to radical cystectomy, with more evidence supporting its use than partial cystectomy.
• A partial cystectomy provides surgical tissue that helps doctors confirm the cancer stage while avoiding the possible long-term side effects of radiation.

How Do Doctors Plan Bladder-Sparing Surgery?

Planning starts well before the operating room. A thorough evaluation helps the healthcare team decide whether partial cystectomy is safe, realistic, and likely to remove all visible cancer while preserving bladder function.

Staging and Imaging Tests

Staging is the process of determining how far the cancer has grown, including how deeply it has grown into the bladder wall and whether it has spread to nearby lymph nodes or other organs.

For a partial cystectomy to be considered, the disease must be localized, meaning it has not spread beyond the area that surgery can safely treat.

A CT scan of the chest, abdomen, and pelvis may be used to check whether the cancer has spread beyond the bladder. A CT urogram, a type of CT scan that looks closely at the urinary tract, may also be used to evaluate the kidneys, ureters, and bladder.

An MRI of the pelvis may provide more detailed pictures of the bladder and nearby tissues, which can help doctors look for signs that the cancer has grown outside the bladder.

Together, these imaging tests help doctors understand whether the cancer still appears localized. This is an important requirement before partial cystectomy or another bladder-sparing approach is considered.

The Role of Cystoscopy and Lymph Node Evaluation

Presurgery planning requires a thorough cystoscopy (looking inside the bladder) to map the main tumor and check for other growths.

To help find small or flat tumors that may be harder to see, blue light cystoscopy may be used when available. This technique uses a special medicine and light to make cancer cells easier to spot.

Biopsies of the surrounding tissue are taken to rule out hidden CIS, a critical step to confirm the rest of the bladder is healthy enough for a partial removal.

During surgery, pelvic lymph nodes are also removed and examined. Some studies suggest that partial cystectomy combined with adequate pelvic lymph node dissection may lead to cancer outcomes similar to radical cystectomy in carefully selected people. However, the evidence remains limited.

Neoadjuvant Chemotherapy

Cisplatin-based chemotherapy given before surgery is called neoadjuvant chemotherapy. It is a standard treatment option for people with MIBC who are healthy enough to receive it. Neoadjuvant chemotherapy may shrink the tumor and treat microscopic cancer cells — cancer cells that are too small to show up on imaging tests.

Chemotherapy given before surgery — called neoadjuvant chemotherapy — is recommended for people healthy enough to receive it.

For people who can’t safely receive cisplatin, the medical oncology team may consider other treatment options.

Weighing the Benefits and Limitations

Bladder preservation has some advantages, but it also comes with meaningful trade-offs. Understanding both sides helps people make a choice that fits their values and situation.

Potential Benefits of Preserving the Bladder

Keeping the bladder means preserving natural urinary function, though bladder capacity may be reduced after partial resection, which can lead to more frequent urination, urgency, or trouble holding urine.

This approach may reduce some sexual side effects for some people, but sexual outcomes can vary a lot based on the type of surgery, whether nerves can be spared, and a person’s health.

Partial cystectomy may also carry a lower short-term risk of some surgical complications compared with removing the whole bladder.

Some studies report higher quality-of-life scores in people who received partial cystectomy compared to those who underwent radical cystectomy. However, these findings are influenced by who is eligible for the surgery. People who qualify often have less advanced disease and better baseline health.

Understanding Recurrence Risk and Surveillance

The primary drawback of a partial cystectomy is the risk of cancer returning in the remaining part of the bladder, which happens in roughly one-third of cases. While some recurrences are superficial and easily managed, others may eventually require a backup surgery to remove the entire bladder.

Despite this risk, a study confirmed that when the initial cancer is confined to a single area, saving part of the organ offers five-year survival rates comparable to full removal.

Lifelong monitoring is essential after partial cystectomy. Follow-up may include frequent cystoscopy, urine cytology, and imaging scans, especially during the first few years.

Combined with potential short-term side effects like a smaller bladder capacity and more frequent urination, this intensive follow-up can also feel emotionally exhausting. Mental health support may be helpful.

Taking the Next Step

For a carefully selected group, a partial cystectomy offers a way to achieve strong cancer control while keeping natural bladder function. Choosing this path requires a thorough medical evaluation, a clear understanding of recurrence risks, and a firm commitment to lifelong monitoring.

Before your next appointment, write down questions about whether your tumor’s size and location make you a candidate for bladder-sparing surgery. You can also ask for copies of your pathology reports and imaging scans.

Finally, consider speaking with a bladder cancer specialist for a second opinion. Getting another perspective is a common, helpful step that can clarify your options and help you feel more confident about your path forward.

Join the Conversation

On MyBladderCancerTeam, people share their experiences with bladder cancer, get advice, and find support from others who understand.

What does "quality of life" mean to you when facing a bladder cancer treatment decision? Let others know in the comments below.